Background {#Sec1}
==========

Bortezomib (BTZ), as a first-generation proteasome inhibitor, is primarily used for the treatment of relapsed or resistant multiple myeloma. However, painful neuropathy, one of its dose-limiting toxicities, often results in dose reduction or cessation of the first-line treatment, and it usually persists a long period even after the cessation of treatment \[[@CR1], [@CR2]\]. Due to the lack of understanding on the mechanisms underlying bortezomib-induced painful neuropathy, the clinical use of bortezomib is largely limited \[[@CR2]\], which necessitates the further research to identify the underlying mechanism.

Evidences showed that inflammasomes are groups of protein complexes that recognize diverse sets of inflammation-inducing stimuli such as pathogenic or tissue damage \[[@CR3]\]. NACHT leucine-rich-repeat protein (NALP), as a newly discovered inflammasome family, is composed of the NALP protein, caspase-1, and the adaptor and is implicated in multiple neuroinflammation-related disorders \[[@CR4]\]. Notably, studies have demonstrated that the upregulation of peripheral NALP1 inflammasome induces peripheral sensitization and contributes to the complex regional pain syndrome \[[@CR5], [@CR6]\]. Furthermore, the increase of NALP1 inflammasome is involved in neuropathic pain induced by chronic constriction injury (CCI) \[[@CR7]\]. However, whether the expression of NALP1 inflammasome in dorsal horn contributes to chemotherapeutic drug-induced persisted pain has not been previously described.

Silent information regulator 1 (SIRT1), as a member of sirtuin family, is involved in a wide variety of cellular processes including inflammation, immune, apoptosis, and metabolism \[[@CR8]--[@CR10]\]. In central nerve system, SIRT1 can also modulate synaptic plasticity and memory formation \[[@CR11], [@CR12]\]. Recently, SIRT1 has been reported to be involved in the development of chronic pain. Spinal SIRT1 expression was downregulated in the mouse or rat with chronic constriction nerve injury, and SIRT1 activator SRT1720 ameliorated CCI-induced neuropathic pain \[[@CR13], [@CR14]\]. However, whether SIRT1 participated in the chemotherapeutic drug-induced persistent pain remains unclear. In addition, previous studies showed that SIRT1 negatively regulated the expression of NLRP3 inflammasome in the traumatic brain injury \[[@CR15]\] and vascular endothelial cells \[[@CR16]\]. Notably, accumulating evidences have demonstrated that epigenetic modulation of the expression of pain-related inflammatory genes played an important role in the development and maintenance of neuropathic pain \[[@CR17], [@CR18]\]. Currently, whether the potential dynamic adaptation of SIRT1 regulates the NALP1 expression in the dorsal horn, and the underlying epigenetic mechanism, remains largely unknown.

Methods {#Sec2}
=======

Animals {#Sec3}
-------

Male Sprague-Dawley rats (200-250 g) and male C57BL/6 mice (20--30 g) were obtained from the Institute of Experimental Animals of Sun Yat-Sen University. *STAT3*^flox/flox^ mice (ID: 016923) were commercially purchased from the Jackson Laboratory. All animals were housed separately under controlled conditions (23 ± 1 °C, 55 ± 3% humidity, 6am to 6pm alternate light/dark cycles) with food and tap water ad libitum. All animals were randomly assigned to different groups. The experimental protocols were approved by Sun Yat-Sen University Animal Care and Use Committee and were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize the number and the suffering of animals used.

Injection of drug and adenovirus-associated vector {#Sec4}
--------------------------------------------------

Bortezomib (Haoran Biological Technology CO, Shanghai) was intraperitoneally injected at 0.4 mg/kg once per day for consecutive 5 days as described previously \[[@CR19]\]. Control animals received an equivalent volume of vehicle saline. siRNA, which are chemically modified for the enhanced stability with methylation and for high efficiency delivery with cholesterol-conjugation, were commercially obtained from Ribobio. The saline was used to siRNA delivery. Resveratrol (50 μg/10 μl, 250 μg/10 μl, and 500 μg/10 μl; Sigma-Aldrich, USA), NALP1 siRNA (50 μg/10 μl; Ribobio, China), scrambled siRNA (50 μg/10 μl; Ribobio, China), SIRT1 siRNA (50 μg/10 μl; Ribobio, China), S3I-201 (100 μg/10 μl; Selleck Chemicals, USA), or vehicle saline (10 μl) was intrathecally administrated 30 min prior to bortezomib treatment and maintained for 10 days.

4 μl of recombinant adeno-associated virus encoding Cre and green fluorescent protein (GFP) marker (AAV8-Cre-GFP, Beijing Vector Gene Technology Company Ltd.) was intrathecally injected into the subarachnoid space of L5-L6 spinal cord in *STAT3*^flox/flox^ mouse. In the control group, the same amount of AAV8-GFP was intrathecally administrated in *STAT3*^flox/flox^ mouse. Bortezomib was intraperitoneally administrated on day 21 after the injection of virus.

Lumbar subarachnoid catheterization and behavioral assessment {#Sec5}
-------------------------------------------------------------

For intrathecal injection, after animals were anesthetized intraperitoneally with 50 mg/kg sodium pentobarbital, polyethylene intrathecal catheters (PE-10, Becton Dickinson, USA) were implanted into animals as described previously \[[@CR19]\]. In brief, the catheter was inserted into the lumbar subarachnoid space between fifth and sixth lumbar vertebrae with the tip of the catheter located near the L5 spinal segmental level. Following intrathecal implantation of catheters, animals were allowed 5 days to recover from surgery prior to subsequent drug injection, and any animals with hind limb paresis or paralysis were excluded from the present study. 10 μl of 2% lidocaine was injected to confirm correct catheter position, as indicated by transient bilateral hind limb paralysis.

Mechanical allodynia was tested using von Frey filaments applied to the plantar region of the hind paw as described previously. Briefly, animals were placed in a plastic box on a metal mesh and were allowed to acclimate for 30 min before testing. von Frey filaments of different bending force were applied alternately to the midplantar surface of hind paw. Mechanical allodynia of each animal was assessed by the hind paw mechanical withdrawal threshold. A nociceptive response was defined as a brisk paw withdrawal or paw flinching following von Frey filament application. Each trial was repeated for three times at 2 min intervals. The 50% paw withdrawal threshold was calculated for each animal following a previous validated up-down procedure \[[@CR20]\]. The behavioral tests were conducted by an experimenter who was blinded to all treatments.

RNA extraction and real-time quantitative PCR {#Sec6}
---------------------------------------------

Total RNA was extracted from dorsal horn (L4--L6) tissues by Trizol reagent (Invitrogen, USA). SYBR Green qPCR SuperMix (Invitrogen, USA) and ABI PRISM7500 Sequence Detection System were used for real-time quantitative PCR. The reverse transcription reactions were performed using oligo-dT primer and M-MLV reverse transcriptase (Promega, USA) according to the protocol based on the manufacturer's instructions. The amount of synthesized cDNA was evaluated by PCR by using primers specific for NALP1 (rat): forward 5′-GTGGCTGGACCTCTGTTTGA-3′, and reverse 5′-GGCGTTTCTAGGACCATCCC-3′. PCR amplification was carried out with an initial denaturing step at 94 °C for 3 min, then 40 cycles at 94 °C for 10 s, at 58 °C for 20 s, and at 72 °C for 10 s. The relative expression ratio of mRNA in L4--L6 dorsal horn tissues was quantified by the 2^−△△CT^ method \[[@CR21]\].

Western blotting {#Sec7}
----------------

Western blotting was in accordance with the description in our previous study \[[@CR22]\]. Briefly, L4--L6 spinal dorsal horn tissues of animals were removed and homogenized in 15 mmol/l Tris containing a cocktail of proteinase inhibitors and phosphatase inhibitors following animals were anesthetized with 50 mg/kg sodium pentobarbital (i.p.). Next, the lysates of L4--L6 dorsal horn tissues were prepared and separated by gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene fluoride membrane. They were then pre-incubated for 1 h at room temperature in the block buffer. After incubating with diluted primary antibodies against SIRT1 (1:2000, \#ab110304, Abcam, UK), NALP1 (1:1000, \#ab3683, Abcam, UK), phosphorylated STAT3 (1:1500, \#ab76315, Abcam, UK), acetylated histone H3 (1:1000, \#ab8898, Abcam, UK), acetylated histone H4 (1:1000, \#07--329, Millipore, USA), or β-actin (1:2000, \#ab8226, Abcam, UK) overnight at 4 °C, the membranes were incubated in horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. Finally, the bands in the membranes were visualized by enhanced chemiluminescence (ECL, Pierce, USA) as directed by the manufacturer. The bands then were quantified with computer-assisted imaging analysis system (NIH ImageJ).

Immunohistochemistry {#Sec8}
--------------------

Immunohistochemistry was performed as previously described \[[@CR22]\]. Briefly, animals were anesthetized with sodium pentobarbital (50 mg/kg, i.p.), and cardiac perfusion were performed using 0.9% physiological saline, followed by 4% paraformaldehyde in PBS. Next, L4--L6 spinal cord tissues were removed and postfixed in the same fixative overnight and then dehydrated with 30% sucrose. Cryostat sections (16 μm thick) were cut and processed for immunofluorescent staining with primary antibodies for SIRT1 (1:400, Santa Cruz, USA), NALP1 (1:50, Novus Biologicals, USA), phosphorylated STAT3 (1:100, Abcam, UK), NeuN (1:500, Chemicon, USA), GFAP (1:800, Chemicon, USA), or OX42 (1:250, Chemicon, USA). After incubation overnight at 4 °C, the sections were then incubated with cy3-conjugated and fluorescein isothiocyanate-conjugated secondary antibodies for 1 h at room temperature. Isotype IgG was applied in separated sections as control, which did not yield detectable immunosignal. The stained sections were then examined with a Leica (Leica, Germany) fluorescence microscope, and images were captured with a Leica DFC350 FX camera.

Chromatin immunoprecipitation (ChIP) assays {#Sec9}
-------------------------------------------

ChIP assays were carried out using the ChIP Assay Kit (Thermo) as described previously \[[@CR22]\]. The animals were anesthetized with sodium pentobarbital (50 mg/kg, i.p.), and L4--L6 spinal dorsal horn were removed immediately and placed in 1% formaldehyde for 2 min. Then, DNA was fragmented by sonication and digested with micrococcal nuclease. After adding ChIP dilution buffer into DNA sample, 100 μl of the sample was saved as input. The precleared chromatin solution was incubated with anti-p-STAT3 antibody (Cell Signaling Technology, USA) or anti-acetyl-Histone H3 antibody (Abcam, UK) or anti-acetyl-Histone H4 antibody (Millipore, USA) overnight at 4 °C. The "IgG" immunoprecipitation was applied for the negative control. Next day, DNA was purified from the immunecomplexes and input fractions following the antibody/DNA complexes were captured, washed, eluted, and reverse cross-linked. The purified DNA was then resuspended in the nuclease-free water, and real-time quantitative PCR was performed on the sample as described in the above methods. Finally, the ratio of ChIP/input in the L4--L6 spinal dorsal horn was calculated. Primers 5′-CTCAATTCATGGTATTCTAAG-3′ and 5′-GAAGAAATTCATACATCACTG-3′ were designed to amplify a − 1148/− 1057 region relative to the transcription start site of rat *Nalp1* promoter, containing the STAT3-binding site. Primers 5 -TCAAACACCCATTCACAGAGC-3 and 5 -CAAGACGCTCTTCTGTTGTTG-3 were designed to amplify a − 139/− 55 region relative to the transcription start site of mouse *Nalp1* promoter, containing the STAT3-binding site.

Coimmunoprecipitation {#Sec10}
---------------------

Coimmunoprecipitation was performed using the Co-Immunoprecipitation Kit (Thermo Fisher Scientific, USA) as described previously \[[@CR22]\]. Briefly, animals were anesthetized with intraperitoneal injection of sodium pentobarbital (50 mg/kg), and L4--L6 spinal dorsal horn tissues were excised and homogenized in lysis buffer. The anti-p300 antibody (Abcam, UK) or anti-p-STAT3 antibody (Abcam, UK), which immobilized with resin, were used to collect the immune complexes. The eluted complexes from the resin were then analyzed by western blotting using anti-p-STAT3 antibody or anti-p300 antibody after incubation and washes.

Statistical analysis {#Sec11}
--------------------

All data were expressed as the mean values ±SEM, and analyzed with SPSS 20.0 (SPSS, USA). For behavioral tests, one-way or two-way ANOVA with repeated-measures followed by a Tukey post hoc test was carried out. Western blotting and real-time quantitative PCR data were analyzed by two-way ANOVA followed by a Tukey post hoc test. The criterion for statistical significance was *P* \< 0.05. While no power analysis was performed, the sample size was determined according to our and peers' previous publications in painful behavior and pertinent molecular studies.

Results {#Sec12}
=======

Upregulation of NALP1 contributed to bortezomib-induced mechanical allodynia {#Sec13}
----------------------------------------------------------------------------

Consistent with our previous study \[[@CR23]\], intraperitoneal administration of bortezomib (0.4 mg/kg for five consecutive days) markedly decreased the mechanical withdrawal threshold (Fig. [1a](#Fig1){ref-type="fig"}). The results of western blot and PCR showed that the expression of dorsal horn NALP1 protein and mRNA was significantly enhanced on day 5 and 10 following bortezomib treatment (Fig. [1b](#Fig1){ref-type="fig"}, [c](#Fig1){ref-type="fig"}). Double immunofluorescent staining showed that the increased NALP1 was primarily colocalized with NeuN (a neuronal marker), but not with GFAP (an astrocytic marker) or Iba-1 (a microglial marker) (Fig. [1d](#Fig1){ref-type="fig"}). To define the role of NALP1 in bortezomib-induced persistent pain, NALP1 siRNA was continuously administrated into the naive rats for 10 days (50 μg/10 μl, i.t.), which significantly decreased the levels of NALP1 mRNA (Fig. [1e](#Fig1){ref-type="fig"}) and protein (Fig. [1f](#Fig1){ref-type="fig"}) on day 10. Further behavioral study found that knockdown of NALP1 in dorsal horn by intrathecal injection of the NALP1 siRNA significantly attenuated the mechanical allodynia induced by bortezomib (Fig. [1g](#Fig1){ref-type="fig"}).Fig. 1Increased NALP1 in spinal dorsal horn is involved in bortezomib-induced mechanical allodynia. **a** Intraperitoneal administration of bortezomib (0.4 mg/kg for five consecutive days) markedly decreased the mechanical withdrawal threshold. *n* = 12 in each group, \*\**P* \< 0.01 versus vehicle group. The level of NALP1 protein (**b**) and mRNA (**c**) in dorsal horn was significantly upregulated following BTZ treatment. *n* = 6 in each group, \*\**P* \< 0.01 versus the vehicle group. **d** The photographs showed the double staining between neuronal markers (NeuN, red) or astrocyte marker (GFAP, red) or microglia marker (OX42, red) with NALP1 (green) in spinal cord of rats on day 10 following BTZ treatment. *n* = 4 in each group; scale bar, 50 μm. The expression of NALP1 mRNA (**e**) and protein (**f**) in dorsal horn were suppressed on day 10 following consecutive intrathecal injection of NALP1 siRNA for 10 days. *n* = 5 in each group, \*\**P* \< 0.01 versus corresponding scramble siRNA group. **g** Intrathecal delivery of NALP1 siRNA for 10 days attenuated the mechanical allodynia following BTZ treatment. *n* = 12 in each group, \*\**P* \< 0.01 versus vehicle group, ^\#\#^*P* \< 0.01 versus corresponding scramble siRNA group

Reduction of SIRT1 upregulated NALP1 expression and participated in bortezomib-induced mechanical allodynia {#Sec14}
-----------------------------------------------------------------------------------------------------------

Next, we found that the dorsal horn SIRT1 protein expression was significantly decreased on days 5 and 10 following bortezomib treatment (Fig. [2a](#Fig2){ref-type="fig"}). Double immunofluorescent staining showed that SIRT1 was primarily expressed in NeuN-positive cells, but not GFAP-positive and OX42-positive cells (Fig. [2b](#Fig2){ref-type="fig"}). To further confirm the role of SIRT1 in bortezomib-induced persistent pain, we investigated the behavioral response to the artificial manipulation of SIRT1 function in dorsal horn. The results showed that intrathecal injection of specific SIRT1 activator resveratrol at dose of 250 μg or 500 μg, but not 50 μg, for consecutive 10 days attenuated the mechanical allodynia induced by bortezomib (Fig. [2c](#Fig2){ref-type="fig"}). Meanwhile, we specifically downregulated the expression of spinal SIRT1 in normal rats by intrathecal administration of SIRT1 siRNA for consecutive 10 days and then assessed pain behavior. The knockdown efficiency of SIRT1 siRNA was validated by western blotting (Fig. [2d](#Fig2){ref-type="fig"}). Compared with the control group, intrathecal injection of siRNA (50 μg/10 μl) induced mechanical allodynia in the naïve rats (Fig. [2e](#Fig2){ref-type="fig"}).Fig. 2The decrease of SIRT1 in spinal dorsal horn participated to bortezomib-induced mechanical allodynia. **a** Representative histogram and blots revealed the decrease of SIRT1 in spinal dorsal horn following BTZ treatment. *n* = 6 in each group, \*\**P* \< 0.01 versus the vehicle group. **b** The photographs showed double staining between neuronal markers (NeuN, green) or astrocyte marker (GFAP, green) or microglia marker (OX42, green) with SIRT1 (red) in spinal cord of rats on day 10 following BTZ treatment. *n* = 3 in each group; scale bar, 100 μm. **c** Continuous intrathecal injection of resveratrol at dose of 500 μg/10 μl or 250 μg/10 μl, but not 50 μg/10 μl for 10 days ameliorated mechanical allodynia following BTZ treatment. *n* = 12 in each group, \*\**P* \< 0.01 versus the vehicle group, ^\#\#^*P \<* 0.01 versus corresponding vehicle + bortezomib group. **d** Intrathecal injection of SIRT1 siRNA downregulated the SIRT1 expression in dorsal horn. *n* = 3 in each group, \*\**P* \< 0.01 the control group, ^\#\#^*P* \< 0.01 versus corresponding siRNA group. **e** Downregulation of the SIRT1 by SIRT1 siRNA induced the mechanical allodynia in normal rats. *n* = 8 in each group, \*\**P* \< 0.01 the control group

We next determined whether SIRT1 modulated the NALP1 expression in dorsal horn in the rodents with bortezomib treatment. Firstly, the double immunostaining results showed that SIRT1 was co-expressed with NALP1 in spinal dorsal horn in the rats with bortezomib treatment (Fig. [3a](#Fig3){ref-type="fig"}). Furthermore, SIRT1 activation with resveratrol (250 μg/ 10 μl, i.t. for 10 days) prevented the upregulation of NALP1 mRNA and protein on day 10 following bortezomib treatment (Fig. [3b](#Fig3){ref-type="fig"}, [c](#Fig3){ref-type="fig"}). Meanwhile, compared with the control rats, the expressions of NALP1 were upregulated in the rats with intrathecal injection of SIRT1 siRNA (Fig. [3d](#Fig3){ref-type="fig"}). These findings suggested that reduction of SIRT1 induced the increases of NALP1 expression and subsequently contributed to bortezomib-induced mechanical allodynia.Fig. 3SIRT1 modulated the NALP1 expression following bortezomib treatment. **a** The photographs show double staining between SIRT1 (red) with NALP1 (green) in spinal dorsal horn on day 10 following bortezomib treatment. *n* = 4 in each group; scale bar, 50 μm. Intrathecal injection of resveratrol (250 μg/10 μl for 10 days) inhibited the upregulation of NALP1 mRNA (**b**) and protein (**c**) level in dorsal horn of rats on day 10 following BTZ treatment. *n* = 6 in each group, \*\**P* \< 0.01 versus the vehicle group, ^\#\#^*P* \< 0.01 versus the corresponding BTZ group. **d** Intrathecal injection of SIRT siRNA increased the NALP1 expression in normal rats. *n* = 6 in each group, \*\**P* \< 0.01 versus the control group

STAT3 activation induced by SIRT1 reduction contributed to the expression of NALP1 {#Sec15}
----------------------------------------------------------------------------------

Studies showed the activated STAT3 may increase the histone acetylation in promoter region and enhance the expression of inflammation-associated genes \[[@CR22], [@CR24]\], and our previous study indicated that activation of STAT3 contributed to bortezomib-induced mechanical allodynia \[[@CR23]\]. In the present study, we found that p-STAT3 was expressed in SIRT1-positive cells in spinal dorsal horn (Fig. [4a](#Fig4){ref-type="fig"}), and SIRT1 activator resveratrol significantly inhibited the increase of spinal p-STAT3 induced by bortezomib (Fig. [4b](#Fig4){ref-type="fig"}). Further immunoblotting results showed that global acetylation level of H3 (k9) and H4 (k16) was increased in dorsal horn following bortezomib treatment (Fig. [4c](#Fig4){ref-type="fig"}, [d](#Fig4){ref-type="fig"}). Previous studies reported that SIRT1, as a kind of nicotinamide adenine dinucleotide (NAD1)-dependent deacetylase, can preferentially regulate the acetylation of H3 (k9) and H4 (k16) \[[@CR25], [@CR26]\]. Then, we determined whether the histone hyperacetylation resulted from the reduced SIRT1 deacetylase activity or the increased p-STAT activity induced by SIRT1 reduction in dorsal horn in the rats with bortezomib treatment. The TFSEARCH and the JASPAR database' analysis showed that the position − 1127/− 1117 region of *Nalp1* gene exists a potent-binding site for STAT3. Then, DNA precipitated by p-STAT3 antibody or SIRT1 antibody was proceeded to PCR analysis, in which the primers was designed to amplify a 92-bp fragment (− 1148/− 1057) of *Nalp1* promoter flanking STAT3-binding site. The results revealed that the recruitment of p-STAT3 (Fig. [4e](#Fig4){ref-type="fig"}), but not SIRT1 (Fig. [4f](#Fig4){ref-type="fig"}), to *Nalp1* promoter region was significantly enhanced on day 10 in spinal dorsal horn of rats with bortezomib treatment, compared with the vehicle-treated rats. Importantly, the ChIP assay also revealed that H3 (k9) and H4 (k16) acetylation level were increased on the *Nalp1* promoter region flanking the p-STAT3-binding site after treatment with bortezomib on day 10 (Fig. [4g](#Fig4){ref-type="fig"}). These findings suggested that NALP1 upregulation results from STAT3-mediated histone acetylation on the *Nalp1* promoter region flanking the p-STAT3-binding site rather than from a direct action of the SIRT1 reduction after bortezomib treatment.Fig. 4P-STAT3, but not SIRT1, directly mediated the expression of NALP1 following bortezomib treatment. **a** The photographs show double staining between SIRT1 (red) with NALP1 (green) in spinal dorsal horn on day 10 following bortezomib treatment. *n* = 4 in each group; scale bar, 50 μm. **b** Application of resveratrol (i.t.) reduced the increase of p-STAT3 on day 10 following BTZ treatment. *n* = 6 in each group, \*\**P* \< 0.01 versus the vehicle group, ^\#\#^*P* \< 0.01 versus the corresponding BTZ group. BTZ treatment significantly increased the global acetylation of histone H3 (K9) (**c**) and H4 (K16) (**d**) in spinal dorsal horn of rats. *n* = 6 in each group, \*\**P* \< 0.01 versus vehicle group. **e** ChIP results showed the enhanced recruitment of p-STAT3 to Nalp1 gene promoter on day 10 following BTZ treatment. *n* = 5 in each group, \*\**P* \< 0.01 versus vehicle group. **f** The recruitment of SIRT1 to Nalp1 gene promoter did not significantly changed on day 10 in spinal dorsal horn of rats with bortezomib treatment. *n* = 5 in each group, \*\**P* \< 0.01 versus vehicle group. **g** ChIP assay showed BTZ treatment increased the acetylation of histone H3 and H4 on Nalp1 gene promoter region flanking p-STAT3-binding site in rats. *n* = 6 in each group, \*\**P* \< 0.01 versus corresponding vehicle group, ^\#\#^*P* \< 0.01 versus the corresponding vehicle group

Interaction between pSTAT- and P300-mediated histone hyperacetylation in *Nalp1* promoter region induced by bortezomib {#Sec16}
----------------------------------------------------------------------------------------------------------------------

Next, we further explored the mechanism of STAT3-regulating NALP1 expression. Consecutive intrathecal injections of STAT3 inhibitor S3I-201, while decreasing the phosphorylation of STAT3 (Fig. [5a](#Fig5){ref-type="fig"}), significantly reduced the NALP1 upregulation at protein (Fig. [5a](#Fig5){ref-type="fig"}) and mRNA (Fig. [5b](#Fig5){ref-type="fig"}) levels in dorsal horn induced by bortezomib.Fig. 5Activated STAT3 by binding p300 increased the level of acetylated histone H3and H4 on the Nalp1 promoter. Continuous injection of STAT3 activity inhibitor S3I-201 (100 μg/10 μl for 10 days, i.t.) inhibited the upregulation of NALP1 mRNA (**a**) and protein (**b**) level on day 10 following BTZ treatment. *n* = 8 in each group, \*\**P* \< 0.01 versus the vehicle group, ^\#\#^*P* \< 0.01 versus the corresponding BTZ group. **c** A marked green fluoresces in the dorsal horn of mice was observed on day 21 after AAV8-Cre-GFP injection. **d** Local deficiency of STAT3 by intrathecal injection of AAV-Cre-GFP in STAT3^flox/flox^ mice significantly reduced the upregulation of NALP1 protein in spinal dorsal horn induced by BTZ treatment. *n* = 6 in each group, \*\**P* \< 0.01 versus vehicle group, ^\#\#^*P* \< 0.01 versus the corresponding AAV-GFP group. **e** Increased p300 was significantly immunoprecipitated with p-STAT3 antibody in spinal dorsal horn of rats following BTZ administration. *n* = 6 in each group, \*\**P* \< 0.01 versus vehicle group. **f** Increased p-STAT3 was significantly immunoprecipitated with P300 antibody on the different time points after bortezomib treatment. *n* = 6 in each group, \*\**P* \< 0.01 versus vehicle group. **g** Intrathecal application of S3I-201 reduced the increase of acetylated H3 or H4 on Nalp1 gene promoter region containing p-STAT3-binding site on day 10 following BTZ treatment. *n* = 6 in each group, \*\**P* \< 0.01 versus vehicle group, ^\#\#^*P* \< 0.01 versus the corresponding BTZ group. **h** Local deficiency of STAT3 by intrathecal injection of AAV-Cre-GFP into STAT3^flox/flox^ mice decreased the upregulation of H3 or H4 acetylation on Nalp1 gene promoter induced by BTZ. *n* = 6 in each group, \*\**P* \< 0.01 versus vehicle group, ^\#\#^*P* \< 0.01 versus the corresponding AAV-GFP injected BTZ group

A marked green fluoresces in the dorsal horn of mice on day 21 after AAV8-Cre-GFP injection suggested a high efficiency of transfection (Fig. [5c](#Fig5){ref-type="fig"}). Conditional knockout of STAT3 by intrathecal administration of AAV-Cre-GFP in *STAT3*^flox/flox^ mice also inhibited the upregulation of NALP1 protein level induced by bortezomib (Fig. [5d](#Fig5){ref-type="fig"}). Furthermore, the co-immunoprecipitation (Co-IP) results showed that bortezomib treatment markedly increased the histoneacetyl transferase p300 content in the immunocomplex precipitated by p-STAT3 antibody (Fig. [5e](#Fig5){ref-type="fig"}). Similarly, the increased p-STAT3 content at the different time points was also observed in the immunocomplex precipitated by p300 antibody in the dorsal horn lysates. These results confirmed that bortezomib enhanced the interaction between p-STAT3 and p300 (Fig. [5f](#Fig5){ref-type="fig"}). Next, The ChIP assay revealed that intrathecal injection of S3I-201 into rats or AAV-Cre-GFP into *STAT3*^flox/flox^ mice significantly inhibited the bortezomib-induced H3 and H4 hyperacetylation on *Nalp1* promoter region flanking the p-STAT3-binding site (Fig. [5g](#Fig5){ref-type="fig"}, [h](#Fig5){ref-type="fig"}). Taken together, these results suggested that bortezomib induced an enhancement of histone acetylation at the promoter of *Nalp1* gene through increasing interaction of p-STAT3 and p300.

Discussion {#Sec17}
==========

In the present study, we first found that reduction of SIRT1 induced activation of STAT3, and subsequently upregulated the expression of NALP1 in dorsal horn, and contributed to the mechanical allodynia induced by chemotherapeutic drug bortezomib. Bortezomib increased the NALP1 expression in spinal dorsal horn neurons, and intrathecal application of NALP1 siRNA attenuated the bortezomib-induced mechanical allodynia. In addition, bortezomib treatment decreased the SIRT1 expression in dorsal horn neuron, and intrathecal injection of SIRT1 activator resveratrol ameliorated the NALP1 upregulation and mechanical allodynia following bortezomib treatment. Moreover, knockdown of SIRT1 using the SIRT1 siRNA increased the NALP1 expression and induced mechanical allodynia in normal animal. These results demonstrated the critical role of SIRT1 reduction in NALP1 upregulation in dorsal horn and pain behavior induced by bortezomib. We further found that SIRT1 reduction increased the phosphorylation of the transcript factor STAT3 in dorsal horn in the rodents with bortezomib treatment. We also found that interaction between p-STAT and p300 in *Nalp1* promoter region enhanced the histone acetylation and facilitated the expression of NALP1 in dorsal horn in the rodents with bortezomib treatment. Taken together, these findings suggested a new mechanism by which SIRT1 regulated NALP1 expression in dorsal horn neurons and subsequently contributed to bortezomib-induced mechanical allodynia.

In our study, we observed for the first time that application of chemotherapeutic drug bortezomib upregulated NALP1 protein and mRNA expression in dorsal horn, and intrathecal injection of NALP1 siRNA attenuated the mechanical allodynia induced by bortezomib. It is well known that NALP1 inflammasome is responsible for the activation of pro-inflammatory caspases \[[@CR4]\], and inhibition of NALP1 inflammasome activation significantly decreases IL-1β maturation and Pro-IL-1β synthesis \[[@CR27]\]. So, it is possible that inflammatory cytokines such as IL-1β induced by NALP1 inflammasome significantly contribute to the painful neuropathy induced by bortezomib. It was consistent with the previous evidence that spinal NALP1 inflammasome regulated spinal IL-1β maturation and contributed to the development of CCI-induced neuropathic pain \[[@CR28]\]. While the possibility existed that the analgesia induced by intrathecal dosing scheme in the present study might be partially supplemented with its potential effect on DRG neurons or their central terminals, our results at least showed that the spinal cord NALP1 signaling was critically involved in the BTZ-induced mechanical allodynia.

The present study also showed that SIRT1 was also involved in the painful neuropathy induced by chemotherapeutic drug bortezomib, as evidenced by our findings that recovery of SIRT1 activity with resveratrol attenuated the bortezomib-induced mechanical allodynia. Moreover, artificial suppression of SIRT1 activity by specific siRNA significantly decreased the withdrawal threshold in naive rats. Similar findings were reported by the previous studies that the SIRT1 expression and activity were decreased in the spinal cord in rodent models with CCI, and modulations of SIRT1 activity by resveratrol ameliorated the development of CCI-induced neuropathic pain \[[@CR13], [@CR14], [@CR29]\]. Study also showed that the SIRT1 downregulation increased H3 acetylation levels at Grm1/5 promoter region, consequently enhanced the mGluR1/5 expression, and contributed to the neuropathic pain in type 2 diabetic rats. Notably, although the present study showed that the SIRT1 downregulation promoted the NALP1 expression, bortezomib did not decrease the SIRT1 binding at NALP1 promoter regions flanking the p-STAT3-binding site relative to the control group, suggested that the increases of NALP1 might not directly result from the reduced deacetylase activity following SIRT1 decrease induced by bortezomib. Our previous and peer's studies showed that STAT3, a transcriptional factor, was involved in the neuropathic pain induced by nerve injury or chemotherapeutic drug \[[@CR19], [@CR23], [@CR30]\]. Furthermore, studies showed that SIRT1 suppressed STAT3 phosphorylation, which promoted the transcription of gluconeogenic gene \[[@CR31]\]. In the present study, we found that the activation of SIRT1 by resveratrol significantly inhibited STAT3 phosphorylation and decreased the recruitment of p-STAT3 to the *Nalp1* promoter, which suppressed the expression of NALP1 in the spinal dorsal horn of rats following bortezomib treatment. In conclusion, SIRT1 reduction induced STAT3-mediated epigenetic upregulation of NALP1 in dorsal horn and contributed to the persistent pain induced by chemotherapeutic drug bortezomib.

Conclusions {#Sec18}
===========

Taken together, our data demonstrated a new epigenetic mechanism by which SIRT1 regulated NALP1 expression in dorsal horn neurons and subsequently contributed to bortezomib-induced mechanical allodynia. Importantly, the NALP1 upregulation resulted from STAT3-mediated histone acetylation on the *Nalp1* promoter region that was induced by SIRT1 reduction after bortezomib treatment.

BTZ

:   Bortezomib

CCI

:   Chronic constriction injury

IL-1β

:   Interleukin-1β

mRNA

:   Messenger RNA

NALP1

:   NACHT leucine-rich-repeat protein

siRNA

:   Small interference RNA

SIRT1

:   Silent information regulator 1

STAT3

:   Signal transducers and transcription activator 3

Funding {#FPar1}
=======

This study was supported by the National Natural Science Foundation of China (NSFC) (31171281, 1371236, 31301116, 81600959), Major International Cooperation Projects in Universities in Guangdong Province (2015KGJHZ020), Guangdong Science and Technology Project (2014750), Guangzhou Education Bureau Science and Technology Project (10A044), Guangzhou Science and Technology Project (20160299), the Foundation for Fostering the Scientific and Technical Innovation of Guangzhou University (20169203), and key project of production and research of Guangzhou University (20180108).

Availability of data and materials {#FPar2}
==================================

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

CK participated in and designed all of the experiments, analyzed the data, and wrote the manuscript. JF and JY performed the western blot, PCR, and immunohistochemistry. ZFL performed the experiment of ChIP and co-IP. WJX performed the behavioral assessment and analyzed the data. CCL supervised the experiments, analyzed the data, and wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval {#FPar3}
===============

All procedures were approved by the Sun Yat-Sen University Animal Care and Use Committee and carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
